By Fineline Cube 
Switzerland-based Novartis (NYSE: NVS) announced this week that it has received another indication approval from the National Medical Products Administration (NMPA) for its CDK4/6 inhibitor Kisqali (ribociclib). The approval is for use in combination with an aromatase inhibitor (AI) as adjuvant therapy for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative early breast cancer patients with a high risk of recurrence.
Kisqali’s Global Presence
Kisqali has already been approved as a treatment for breast cancer in over 100 countries worldwide. In China, it was first approved in January 2023 as an initial endocrine therapy for premenopausal or perimenopausal female patients with HR+, HER2-, locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor.-Fineline Info & Tech